Learning MRI-based classification models for MGMT methylation status prediction in glioblastoma

High-grade brain neoplasms, such as glioblastoma (GBM), are among the most aggressive and difficult-to-treat forms of cancer. Temozolomide, a DNA alkylating agent, is the standard chemotherapeutic agent approved by the U.S. Food and Drug Administration for first-line treatment of GBM. Temozolomide causes alkylation at the O6 guanine position of DNA and induces cytotoxic effects and apoptosis in cancer cells. Recent molecular studies have demonstrated that the methylation status of the O6 methylguanine-DNA methyltransferase (MGMT) gene promoter is a predictor of response to temozolomide and a prognostic indicator of survival time in patients with temozolomide-treated GBM [1 –6].

Source: Computer Methods and Programs in Biomedicine - December 30, 2016 Category: Bioinformatics Authors: Vasileios G. Kanas, Evangelia I. Zacharaki, Ginu A. Thomas, Pascal O. Zinn, Vasileios Megalooikonomou, Rivka R. Colen Source Type: research